CAMBELL INTERNATIONAL HOLDING CORP.
CAMBELL INTERNATIONAL HOLDING CORP. (BITMIS): 1 pipeline candidate. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
D/E -1.31 · 0% dilution
Lead: Approved
1 candidate
N/A
N/A
A transparent, data-derived signal for CAMBELL INTERNATIONAL HOLDING CORP.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$113K
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| voraxaze | Approved |
Frequently asked questions
How many drug candidates are in CAMBELL INTERNATIONAL HOLDING CORP.'s pipeline?
CAMBELL INTERNATIONAL HOLDING CORP. (BITMIS) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is CAMBELL INTERNATIONAL HOLDING CORP.'s lead drug candidate?
CAMBELL INTERNATIONAL HOLDING CORP.'s most advanced tracked candidate is voraxaze (Approved) for 1 INDICATIONS AND USAGE VORAXAZE is indicated to reduce toxic plasma methotrexate concentration (greater than 1 micromole per liter) in adult and pediatric patients with delayed methotrexate clearance (plasma methotrexate concentrations greater than 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) due to impaired renal function. Limitations of Use: VORAXAZE is not recommended for use in patients who exhibit the expected clearance.
Get the full picture on CAMBELL INTERNATIONAL HOLDING CORP.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.